Effect of beta-glucuronidase on urinary benzodiazepine concentrations determined by fluorescence polarization immunoassay
(1995) In Clinical Chemistry 41(6 Pt 1). p.920-923- Abstract
- In samples from patients treated with oxazepam, beta-glucuronidase increased the immunoreactivity of urinary benzodiazepines analyzed by fluorescence polarization immunoassay (FPIA). Increasing concentrations of beta-glucuronidase added to samples from drug-free controls did not influence the results. In the absence of beta-glucuronidase, 22 of 35 samples from patients undergoing detoxification gave positive results at a cutoff concentration of 200 micrograms/L. Pretreatment with beta-glucuronidase increased the number of drug-positive samples to 33. The drug-negative samples were obtained from two patients who had been oxazepam-free for at least 1 week. Thus, beta-glucuronidase can be used to increase the sensitivity of the urinary... (More)
- In samples from patients treated with oxazepam, beta-glucuronidase increased the immunoreactivity of urinary benzodiazepines analyzed by fluorescence polarization immunoassay (FPIA). Increasing concentrations of beta-glucuronidase added to samples from drug-free controls did not influence the results. In the absence of beta-glucuronidase, 22 of 35 samples from patients undergoing detoxification gave positive results at a cutoff concentration of 200 micrograms/L. Pretreatment with beta-glucuronidase increased the number of drug-positive samples to 33. The drug-negative samples were obtained from two patients who had been oxazepam-free for at least 1 week. Thus, beta-glucuronidase can be used to increase the sensitivity of the urinary benzodiazepine FPIA without reducing the specificity of the method. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1109585
- author
- Simonsson, Per LU ; Lidén, Anders and Lindberg, Stellan
- organization
- publishing date
- 1995
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Chemistry
- volume
- 41
- issue
- 6 Pt 1
- pages
- 920 - 923
- publisher
- American Association for Clinical Chemistry
- external identifiers
-
- pmid:7768013
- scopus:0028978014
- ISSN
- 0009-9147
- language
- English
- LU publication?
- yes
- id
- 3d6fac71-7947-4aaf-bd75-634345faa141 (old id 1109585)
- alternative location
- http://www.clinchem.org/cgi/reprint/41/6/920
- date added to LUP
- 2016-04-01 11:55:05
- date last changed
- 2021-01-03 04:25:49
@article{3d6fac71-7947-4aaf-bd75-634345faa141,
abstract = {{In samples from patients treated with oxazepam, beta-glucuronidase increased the immunoreactivity of urinary benzodiazepines analyzed by fluorescence polarization immunoassay (FPIA). Increasing concentrations of beta-glucuronidase added to samples from drug-free controls did not influence the results. In the absence of beta-glucuronidase, 22 of 35 samples from patients undergoing detoxification gave positive results at a cutoff concentration of 200 micrograms/L. Pretreatment with beta-glucuronidase increased the number of drug-positive samples to 33. The drug-negative samples were obtained from two patients who had been oxazepam-free for at least 1 week. Thus, beta-glucuronidase can be used to increase the sensitivity of the urinary benzodiazepine FPIA without reducing the specificity of the method.}},
author = {{Simonsson, Per and Lidén, Anders and Lindberg, Stellan}},
issn = {{0009-9147}},
language = {{eng}},
number = {{6 Pt 1}},
pages = {{920--923}},
publisher = {{American Association for Clinical Chemistry}},
series = {{Clinical Chemistry}},
title = {{Effect of beta-glucuronidase on urinary benzodiazepine concentrations determined by fluorescence polarization immunoassay}},
url = {{http://www.clinchem.org/cgi/reprint/41/6/920}},
volume = {{41}},
year = {{1995}},
}